Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 20...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 30, 2024

THE KIDS MENTAL HEALTH FOUNDATION HOSTS INAUGURAL "FAMILY DAY CELEBRATION" TO KICK OFF MENTAL HEALTH AWARENESS MONTH • SHATTERPROOF AND ANTHEM BLUE CROSS FOUNDATION PARTNER TO REDUCE HEALTHCARE STIGMA AROUND A SUBSTANCE USE DISORDER IN CALIFORNIA • IEI Announces Groundbreaking e-Paper Display Solution for Sustainable Communication • EY Announces Avelo Airlines Founder Andrew Levy as an Entrepreneur Of The Year® 2024 Gulf South Award Finalist • Marin Software Launches AI-powered Anomaly Detector to Unlock Growth in Performance Marketing Campaigns • Third Coast Bancshares, Inc. Celebrates Earth Month 2024, Reinforcing its Commitment to Impact & Sustainability • Hyliion and Victory Execute Letter of Intent to Deploy up to 10 KARNO™ Generators to H2 Energy Group • WEF Special Meeting Concludes in Riyadh With World Leaders Calling for Clear, Irreversible Path to Peace and Prosperity as Top G • Chegg Announces Appointment of Nathan Schultz as Chief Executive Officer • Joby Expands California Manufacturing Facility, Rolls Second Aircraft Off Production Line • POTTS LAW FIRM: WEST TEXAS WOMAN FILES MULTI MILLION DOLLAR LAWSUIT AGAINST TRUCKING COMPANY • Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship • Athletes, Entrepreneurs and Investors Gather in Detroit During the Draft to Discuss Working Together to Build Community and Gene • MemorialCare Miller Children's & Women's Hospital Long Beach Named Official Children's Hospital of Angels Baseball & Log • Xavier Ochsner College of Medicine Announces Founding Dean and Location in Downtown New Orleans at Benson Tower • Coursera Reports First Quarter 2024 Financial Results • LSB Industries, Inc. Reports Operating Results for the 2024 First Quarter • WuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment • Welltower Reports First Quarter 2024 Results • The Grant Sherpa and WorkForce Strategies International Announce a Revolutionary Solution to Address the Skills Gap Crisis

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

WATERTOWN, Mass. , April 17 /Businesswire/ - Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company’s SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain.

The poster presentation includes primary and post-hoc analyses from the double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, a 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease.

Poster Title: “Efficacy and Safety of EDP-235 in Non-Hospitalized Adults with Mild or Moderate COVID-19: Results from the Phase 2 SPRINT Study”

Abstract Number: 02980

Poster Number: PO423

Day: April 27, 2024

Time: 12:00 p.m. CEST / 6:00 a.m. ET

Session Location: Poster Area

Session Title: COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)

Presenter: Scott T. Rottinghaus, M.D., Chief Medical Officer, Enanta Pharmaceuticals, Inc.

The scientific program for ESCMID Global 2024 can be found at https://www.eccmid.org/scientific-programme

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus infection (HCV) and is sold by AbbVie in numerous countries under the trade names MAVYRET^®(U.S.) and MAVIRET^®(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit http://www.enanta.com for more information.